Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Sees No "Systemic" Problems From Cancer Rx Payment Cuts

This article was originally published in The Pink Sheet Daily

Executive Summary

Incoming Centers for Medicare & Medicaid Services Administrator McClellan says the agency will "closely" monitor whether beneficiary access is impacted by reimbursement changes for Part B drugs.

You may also be interested in...

Paraplatin, Gemzar Medicare Payments Increased For 2004; CMS Boosts Nine Drugs Effective April 1

Camptosar and Avonex will also receive higher reimbursements. Changes reflect data submitted by manufacturers under AWP "exceptions" process.

CMS Administrator Nominee McClellan Clears Senate, Could Begin Week Of March 15

Major tasks facing the new Centers for Medicare & Medicaid Services chief include rolling out the Medicare Rx discount card program by May and drafting rules for the full drug benefit.

Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says

The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts